Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03514303
Other study ID # Microassay study-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2018
Est. completion date June 2019

Study information

Verified date January 2018
Source United Allergy Services
Contact William W Wagoner, BS
Phone 210-679-3926
Email william.wagoner@unitedallergy.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to evaluate the potential correlation of the results of allergen-specific skin prick tests (SPT) to that of allergen-specific microarray determination (microassay test). Subjects who meet enrollment criteria, after signing an IRB approved consent form, will perform a minor finger prick blood draw and blot to be mailed off for microassay analysis. Specific statistical analysis will be done to assess all potential correlations between SPT and microassay. This study design should enable assessment of the level of correlation between SPT results and microassay results for specified allergens within a cohort of subjects with allergic rhinitis.


Description:

Prospective subjects for study entry will initially be screened by the results of their allergy skin test that were acquired within the past two years. In order to be a prospective subject positive SPT results of five of the following ten allergens will be required: Dust Mite, Ragweed, Cat Dander, Johnson Grass, Bermuda Grass, Timothy Grass, Oak, Cladosporium, Dog Dander, and Cockroach. After signing an IRB approved consent form, these patients will undergo a finger prick blood draw and blot. This study will be conducted in compliance with the protocol, GCP and applicable regulatory requirements.

Subjects 18 years of age or over who have never initiated a course of allergy immunotherapy or have not completed more than three months of SCIT immunotherapy will be enrolled.

Sub-investigator(s) will screen patient charts from a database of patients previously tested using the UAS protocol. Patients that qualify based on inclusion criteria will be contacted by phone and asked if they would be willing to participate in this study.

Subject arrives to the clinic and all inclusion and exclusion criteria are verified by their primary physician and the sub-investigator. Sub-investigator insures that the IRB verified consent form is signed and that the patient has no questions. Subject or sub-investigator will perform the finger prick and blot using the instructions listed on the Allergenex sample collection packet. The sample will be mailed to Spiriplex to be analyzed using their microarray device. The microassay results will be sent to the primary investigation site for correlation analysis with the previously logged SPT results. These results will be blinded to the statisticians and researchers that will be determining potential correlation between SPT and microassay results.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 2019
Est. primary completion date February 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects 18 years of age or over who have never initiated a course of allergy immunotherapy or have not completed more than three months of subcutaneous immunotherapy will be enrolled.

Exclusion Criteria:

- Subjects with bleeding disorders or a history of vasovagal reactions to blood draws will not be enrolled in this study.

Study Design


Intervention

Diagnostic Test:
Spiriplex Allergenex Microassay
A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Locations

Country Name City State
United States United Allergy Services San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
United Allergy Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Microassay Tests Completion All patients will be tested by microassay for the 10 allergen groups for comparison to historic skin prick tests of the same 10 allergens. 2-3 months
See also
  Status Clinical Trial Phase
Completed NCT03315611 - Study to Assess the Effect of "Eucerin AtopiControl" on Dermal Symptoms in Patients With Atopic Dermatitis N/A
Completed NCT05824637 - Validation and Reproducibility of S.P.A.T. With Allergens N/A
Completed NCT05301647 - Mometasone Furoate Nasal Spray in Italian Children
Completed NCT03816800 - Iron and Pollen Allergy in Women N/A
Not yet recruiting NCT05532566 - Quercus Ilex and Quercus Robur Allergen Extracts Standardisation N/A
Not yet recruiting NCT05533385 - Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. N/A
Not yet recruiting NCT06167564 - Allergy Diagnostic Test Based on Microchip Technology N/A